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Available online 5 May 2016Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains
cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4+ T cells.
It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immu-
nological damage.We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less
sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that
harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change
because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies
with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility
differences are potentially inﬂuenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using
virus in the presence of autologous plasma and activated CD4+ T cells led to the emergence of a CXCR4-utilizing
virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral
immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates
disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In nearly all cases HIV-1 infection leads to a progressive loss of
CD4+ T cells, and both host immunologic factors and viral characteris-
tics inﬂuence the rate of progression towards AIDS. Although HIV-1 can
enter target cells by either using the C-C chemokine receptor 5 (CCR5)
or CXC-chemokine receptor 4 (CXCR4) co-receptor after CD4 receptor
engagement (Deng et al., 1996; Feng et al., 1996), presence of syncy-
tium-inducing (SI) CXCR4-using viruses is associated with accelerated
disease progression (Koot et al., 1993; Richman and Bozzette, 1994;
Connor et al., 1997). In general, viruses that exclusively utilize the
CCR5 receptor (termed R5 or non-syncytium-inducing (NSI)) establish
initial infection, and these viruses persist throughout the course of dis-
ease (Connor et al., 1997; van't Wout et al., 1994; Schuitemaker et al.,
1992). During the chronic phase of infection, some individuals have a
dual-mixed (DM) population consisting of R5 viruses and CXCR4-of Medicine, 650 Albany Street,
. This is an open access article underusing variants, which can either only use CXCR4 (termed X4) or be
dual-tropic that can engage both co-receptors (termed dual or R5X4)
(Schuitemaker et al., 1992; Connor et al., 1997). Previous studies have
not clariﬁed if CXCR4-using viruses accelerate disease progression or if
faster CD4+ T cell decline facilitates the emergence of DM virus popu-
lations. Deciphering mechanisms for the emergence of CXCR4-utilizing
variantswill provide insights into this viral factor important for progres-
sion towards AIDS.
It is generally agreed that R5 variants give rise to R5X4 viruses,
which can further evolve to X4 HIV-1 (Pastore et al., 2004). Speciﬁc
modiﬁcations in the envelope glycoprotein (env) variable loop 3 (V3),
which binds the co-receptor, are required for the transition from R5 to
X4 virus (Huang et al., 2007; Chesebro et al., 1996; Cocchi et al.,
1996). The selective pressures which induce the transition from CCR5
to CXCR4 usage during the natural course of infection remain poorly un-
derstood. It has been suggested that CXCR4-using viruses potentially
emerge because of a reduced number of susceptible CCR5+ target
cells or replication differences in various immune cells among the vari-
ants that use different co-receptors (Regoes and Bonhoeffer, 2005;
Ribeiro et al., 2006). Indeed, individuals heterozygous for a 32 basethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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receptor on their cells, have an increased likelihood of harboring
CXCR4-using viruses compared to people with both wild-type alleles
(Brumme et al., 2005; Henrich et al., 2014). Other non-mutually exclu-
sive hypotheses argue that CXCR4-utilizing variants arise because of
random mutations, and these new viruses persist because declining
adaptive and innate immune responses fail to clear the less ﬁt dual-
tropic and/or X4 HIV-1. Previous studies have also suggested that neu-
tralizing antibody (nAb) pressure do not drive co-receptor switching
(Trkola et al., 1998; Monteﬁori et al., 1998; Cecilia et al., 1998; Lacasse
et al., 1998). Other investigations have argued that CXCR4-using viruses
are highly neutralization susceptible, and the variants that can use the
CXCR4 receptor only emerge after collapse of the humoral immune re-
sponse (Bunnik et al., 2007; Ho et al., 2007). Within weeks to months
after HIV-1 acquisition, infected individuals develop nAbs against their
autologous viruses, but the virus changes its env to escape this humoral
response (Richman et al., 2003; Wei et al., 2003). Neutralization resis-
tance is frequently associated with modiﬁcations in and around the
env variable portions, such as the env V1–V2 and V3 loop (Sagar et al.,
2006, Rong et al., 2009, Moore et al., 2009). In a cohort of HIV-1 subtype
C (HIV-1C) infected individuals, we have previously shown that the env
quasispecies diversity was signiﬁcantly higher among individuals with
DM as compared to strictly R5 viruses (Lin et al., 2012). In addition,
we observed that all HIV-1C X4 as compared to R5 variants had either
a 2 amino acid insertion prior to or basic amino acid substitutions in
the generally invariant V3 loop crown. Together, these observations
led us to hypothesize that difference in host antibody responses drive
the greater env diversity observed in individuals with DM as compared
to R5 virus populations, and the V3 loop genotypic signatures associated
with X4 variants potentially modify neutralization susceptibility. We
also postulated that the emergence of speciﬁc host antibodies in some
but not all individuals force env sequence and structural changes.
These env modiﬁcations inﬂuence co-receptor switching, and the con-
tinual presence of the speciﬁc host antibodies allows for the persistence
of CXCR4-using viruses. In this study, we examined the role of nAbs on
HIV-1C co-receptor switching.
2. Materials and Methods
2.1. Subjects
HIV-1 envs were isolated from plasma collected from women in the
Mashi study previously shown to harbor DM virus (Thior et al., 2006).
2.2. Ethics Statement
The use of samples was approved by the institutional review boards
at the Harvard School of Public Health, Partners Healthcare Systems,
Boston University, and by the Botswana Ministry of Health. Investiga-
tors who analyzed the data had no contact with the women enrolled
in the Mashi study, and thus all analysis was done in an anonymous
fashion.
2.3. Viruses
The env expression fragments were generated as previously de-
scribed using bulk nested RT-PCRs (Lin et al., 2010). Brieﬂy, RNA was
isolated from 140 μl of individual plasma samples using QIAamp Viral
RNA mini kit (Qiagen). For each sample, 1st round RT-PCR was per-
formed in triplicate to limit re-sampling (Liu et al., 1996). In order to
minimize possible recombination associated with bulk PCR cloning
(Salazar-Gonzalez et al., 2008; Keele et al., 2008), the RT-PCR reactions
were performed with long extension times, limited cycle numbers,
and use of proofreading polymerase (Lahr and Katz, 2009; Judo et al.,
1998; Meyerhans et al., 1990; Fang et al., 1998). Each reaction was
done with 4 μl of the extracted viral RNA, SuperScript III RT/PlatinumTaq HiFi mix (ThermoFisher Scientiﬁc), and an extension time of
7 min for each of the 20 cycles. These 1st round reactions were com-
bined and cloned using TOPO TA cloning (Invitrogen). A CMV promoter
was attached to each individually isolated env clone using overlap PCR.
All primers and ampliﬁcation conditions have been described previous-
ly (Lin et al., 2010). All env sequences have been submitted to Genbank
previously (accession numbers KF770248–KF770455, KX060565–
KX060578) (Lin et al., 2012). Pseudotyped viruses were generated by
co-transfecting HEK293T cells with the CMV promoter PCR product at-
tached to the ampliﬁed env and an env deﬁcient HIV-1 backbone
(pNL4-3R-E-) plasmid expressing luciferase using the Fugene protocol
(Roche Molecular Biochemicals).2.4. Generation of Replication Competent Viruses
Replication competent recombinant viruses were generated with
minor modiﬁcations from a previously described protocol
(Chatziandreou et al., 2012). In the majority of cases, we found that
full-length HIV-1C envs did not yield replication competent recombi-
nant viruses when incorporated into a NL4-3 (HIV-1B) or Q23-17
(HIV-1A) background (Etemad et al., 2014; Pena-Cruz et al., 2013). Be-
cause the same envs yielded infectious pseudotypes, we assumed that
incompatible cis interactions between the env tail and matrix protein
accounted for the lack of infectious virus (Freed and Martin, 1995). To
overcome this issue, we generated a plasmid pCMV-Q23-
PBS→ LTRΔEnvEcto in which the env ecto-domain was replaced with
a uracil biosynthesis (URA3) gene. Brieﬂy, the env ecto-domain in
pCMV-Q23-17-PBS → LTR was replaced with URA3 PCR product,
which was ampliﬁed with the primers AGAAAGAGCAGAAG
ACAGTGGCAATGATTAATTAAACCACCTTTTCAATTCATC and AAGCCT
CCTACTATCATTATCTGATATAATTAAATTGAAGC from pRS316. The
underlined portions correspond to primer sequences used to amplify
env ectodomains (HXB2 env amino acid numbering 1–692) from sub-
ject samples, and the sequences in italics contain a PacI restriction site.
Different env ecto-domains were shuttled into Q23 plasmid by
transforming yeast with pCMV-Q23-PBS → LTRΔEnvEcto linearized
with PacI and ampliﬁed env ecto-domain PCR products from subject
samples. Replication competent viruses were generated by co-
transfecting HEK293T cells with a plasmid containing the subject env
ecto-domain within pCMV-Q23-17-PBS → LTR and another plasmid
with Q23–17 sequences from 5′ LTR to early portion of gag, pCMV-
Q23-17-LTR→ Gag4 (Chatziandreou et al., 2012). All virus stocks were
collected 48 h post transfection and titered on TZM-bl cells.2.5. Reagents
The pNL4-3R-E- plasmid, U87 and TZM-bl cell lines, and VRC01 and
10E8monoclonal antibody (mAb)were obtained through the NIH AIDS
Reagent Program. The 293T cells were obtained from American Type
Culture Collection. The PGT128 and 447-52D mAbs were provided by
International AIDS Vaccine Initiative and Dr. Susan Zolla-Pazner respec-
tively. The CD4-Ig was produced by gene synthesis and cloning into
pcDNA3.1 (Invitrogen).2.6. Co-receptor Phenotype
Co-receptor usagewas determined by assessing entry capacity in the
presence and absence of a co-receptor antagonist on U87 cells express-
ing CD4 and either CXCR4 or CCR5 as previously described (Lin et al.,
2010). To examine replication, U87 cells were incubated with virus
and polybrene (8 μg/ml) for approximately 16 h. Post-incubation, cells
were washed to remove virus. Culture supernatants were examined
for p24gag antigen 5 days post-infection. In all cases NL4-3 (X4) and
YU-2 (R5) were used as controls.
Table 1
Subject demographics and patient characteristics.
Subject Plasma HIV
(copies/ml)
CD4 count
(cells/μl)
Previous ARTa Env variants
R5 Dual X4
DM8 522,000 43 N 10 0 1
DM146 653,000 172 N 10 8 0
DM159 154,000 116 N 5 2 3
DM173 1290 316 N 0 6 3
DM178 230,000 21 Y 8 0 6
DM268 333,000 375 Y 5 0 9
DM269 10,600 319 Y 9 3 0
a Women were sampled either prior to or a minimum of 6 months after the discon-
tinuation of antiretroviral therapy (ART) because of virological failure.
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The codon-optimized gene encoding the R5 DM268M full-length
gp120 was synthesized with a C-terminal Avi-6xHis tag and cloned
into the pcDNA3.1(−) expression vector (Life Technologies). The X4
V3 (DM268Y), differed from the R5 V3 (DM268M) by 5 amino acids;
thesemodiﬁcations and the CD4 knock-outmutationD368Rwere intro-
duced by sequential site-directed mutagenesis using the TagMaster
Site-Directed Mutagenesis Kit (GM Biosciences) (Lin et al., 2012). The
gp120 proteins were expressed by transient transfection using the
expi293 system (Life Technologies). Six days post transfection, culture
supernatants were harvested, ﬁltered, and buffer-exchanged into PBS,
and then puriﬁed using HisTALON Gravity Column Puriﬁcation Kit
(Clontech Laboratories).
2.8. Neutralization Assay
Infection of TZM-bl cells in the absence and presence of 2-fold serial
dilutions was used to estimate the 50% inhibitory concentration (IC50)
as previously described (Etemad et al., 2009). All reported IC50s are
mean estimates from a minimum of 3 independent assays. For virus/
plasma combinations that failed to achieve more than or equal to 50%
inhibition at the highest tested dilution, they were assigned values of
25, which is the midpoint between 0 and highest tested dilution 50.
For virus/mAb combinations, a value equal to the highest tested concen-
trationwas assignedwhen 50% inhibition could not be achieved. For the
neutralization competition assays, plasma at various dilutionswas incu-
batedwithmedia alone or 500 μg/ml of gp120 for 1 h at 37 °C. Viruswas
added, andwellswere incubated for an additional 30min. Then TZM-bls
were added and infections were allowed to proceed for 48 h. Relative
light units generated in the absence (positive wells) as compared to
the presence of plasma were used to estimate % inhibition at speciﬁc
plasma dilutions. For estimating inhibition in the presence DM268M-
R5V3 or DM268M-X4V3 gp120, the positivewells also contained the re-
spective gp120. In all cases, plasmas showed no neutralization capacity
against NL4-3 pseudovirions with a vesicular stomatitis virus (VSV) en-
velope G protein (data not shown). Thus, observed neutralization was
speciﬁc against the HIV-1 envelope.
2.9. ELISA
Plates were coated with gp120 antigen in PBS (pH 7.4) at 2 μg/ml
overnight at 4 °C, blocked with 1% BSA in PBS for 1 h at 37 °C, and
then incubated with serially diluted plasma or antibodies in blocking
buffer for 1 h at 37 °C. Horseradish peroxidase (HRP)-conjugated goat
anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories
Inc.) was added in blocking buffer at 1:10,000 for 1 h at 37 °C. Plates
were washed between each step with 0.1% Tween 20 in PBS and devel-
oped with 3,3′,5,5′-tetramethylbenzidine (TMB) (Life Technologies) for
20 min at room temperature. 1 M sulfuric acid was added to terminate
the reaction and the plates were read at 450 nm.
2.10. Virus Passage
Viruseswere passaged on CD4+T cells in the presence of increasing
concentrations of heat inactivated autologous plasma. Peripheral blood
mononuclear cells (PBMCs) were isolated from HIV-1 negative blood
donors' buffy packs using Ficoll-Hypaque density centrifugation meth-
od. CD4+ T cells were isolated from the PBMCs using magnetic bead
isolation (Stem Cell Technologies). Around 2 × 106 phytohemagglutinin
(PHA) and interleukin-2 (IL-2) activated CD4+ T cells were exposed to
infectious virus in the presence of 20 μg/ml diethylaminoethyl (DEAE)
dextran. Plasma was added after infections were established, generally
two days after infection. Cultures were monitored for viral replication
twice a week using a p24gag antigen assay (Perkin Elmer). The cultureswere fed twiceweeklywith activated CD4+T cells, and plasma concen-
tration was doubled if virus showed continued growth.2.11. Statistical Analysis
In the majority of cases, individual env variant's IC50s was a mean of
3 independent assays. Comparisons within an individual were done
usingWilcoxon rank sum test. For comparisons across multiple individ-
uals, the median IC50 for strains with speciﬁc co-receptor usage was de-
termined for each subject. Inter-subject comparison were done using
Kruskal Wallis test, and pair-wise inter-subject comparisons were
done using the Wilcoxon rank sum test. The matched pairs Wilcoxon
rank sum test was used when all individuals had variants with the co-
receptor usage being compared. All statistical analysis were done
using Stata version 8.0 (Stata Corporation). All p-values are based on
two sided tests.3. Results
3.1. Subjects
Previously, we determined the co-receptor usage in 148 HIV-1C in-
fected women in Botswana, and we found that 22 of them harbored
DM populations while 126 had strictly R5 virus (Lin et al., 2011). Se-
quence characteristics and co-receptor use of individual envs were ex-
amined from 10 of the DM samples that showed relatively high
CXCR4 usage by the phenotypic assay (Lin et al., 2012). Examination
of individuals that harbored X4 variants were prioritized because X4
as compared to co-existing R5 and R5X4 envs were demonstrated to
harbor unique genotypic features (Lin et al., 2012). In addition, individ-
ual envs were not examined from DM samples that demonstrated low
amount of CXCR4 usage in the co-receptor assay because it would likely
require more extensive cloning to isolate CXCR4-using variants. Only 5
from the original 148 samples fulﬁlled these criteria. We chose to exam-
ine an additional 2 samples with only co-circulating R5 and R5X4 vari-
ants. We assessed neutralization susceptibility of a median of 11 co-
circulating envs (range: 9–18) from these 7 different women (Table 1).
The co-existing env populations consisted of X4 and R5 variants in 3
(DM8, DM178, and DM268), R5X4 and R5 variants in 2 (DM146 and
DM269), R5X4 and X4 variants in 1 (DM173), and all three co-receptor
phenotypes in 1 (DM159) of the individuals. An additional 6 DM8 clones
failed to yield other X4 envs. Intra-individual env variants with the
different co-receptor usage were phylogenetically related, which ruled
out contamination and super-infection (Fig. S1). Even though all 88
primary envs examined in this study were generated using bulk-cloning
PCR as described previously (Lin et al., 2010; Lin et al., 2012), all variants
had unique sequences. Thus, we avoided re-sampling the same variant
multiple times,which is a bias often associatedwith the bulk PCR cloning
technique used to isolate the envs in this study (Salazar-Gonzalez et al.,
2008; Keele et al., 2008).
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Toassess neutralization sensitivity differences among88 co-circulat-
ing variants with different observed co-receptor usage, we ﬁrst exam-
ined susceptibility to contemporaneous autologous plasma. In 5
individuals, X4 strains were less sensitive to contemporaneous autolo-
gous plasma as compared to co-existing R5 (DM8, DM178, DM268,
DM159) or R5X4 (DM173) viruses (Fig. 1a–e). Indeed, in 3 individuals
(DM8, DM178, and DM268), the X4 envs were not neutralized above
50% at the highest tested plasma dilution (1:50) (Fig. 1a–c). These
virus-plasma combinations were assigned a value of 25, which is the
mid-point value between 0 and 50, for statistical comparisons. In 3 indi-
viduals (DM178, DM268, and DM173) differences were statistically sig-
niﬁcant (p b 0.05,Wilcoxon rank sum test), while in the other 2 subjects
(DM8 and DM159), limited number of envs with different co-receptor
usage potentially limited the power to detect signiﬁcant differences. In
2 individuals (DM146 and DM269) co-circulating R5 and dual-tropic
envs showed similar neutralization sensitivity (p N 0.05, Wilcoxon
rank sum test) (Fig. 1f–g). Aggregate comparisons were done by esti-
mating a median IC50 for each individual's envs that used different co-
receptor. In aggregate, neutralization IC50s to autologous contempora-
neous plasma was signiﬁcantly different among R5, R5X4, and X4 envs
(p= 0.03, KruskalWallis test). Themedian neutralization susceptibility
to contemporaneous autologous plasma of the X4 viruses (median IC50:
25.0, range: 25.0–140.7) was around 5 fold lower compared to R5 (me-
dian IC50: 136.0, range: 94.2–222.7, p = 0.03, Wilcoxon rank sum test)
and R5X4 viruses (median IC50: 156.5, range: 135.2–160.8, p = 0.03,
Wilcoxon rank sum test) (Fig. 1h).
In preliminary data,we also found anHIV-1B infected individual also
harbored X4 as compared to CCR5-using variants thatwere signiﬁcantly
less sensitive to neutralization by autologous contemporaneous plasma
(Fig. S2). This suggests our observations are not speciﬁc to HIV-1C infec-
tions only. Thus, in every individualwith isolatedX4 viruses (n=6), the
X4 as compared to co-existing R5 and/or R5X4 variants had greater neu-
tralization resistance to autologous contemporaneous plasma (Figs. 1
and S2). Previous studies have noted similar IC50 fold changes among
longitudinally collected viruses to sequential autologous plasma
(Richman et al., 2003). In addition, the observed neutralization response
against contemporaneous viruses in the individuals examined in this
study is not necessarily unique because recent work shows that plasma
and isolated antibodies neutralize some autologous contemporaneousFig. 1. The X4 as compared to co-circulating R5 and R5X4 envs are more neutralization resista
(circles), dual-tropic (triangles), andX4 (boxes) viruses against autologous contemporaneous p
each graph. Y-axis shows the IC50 against autologous contemporaneous plasma as reciprocal dilu
median IC50s within a subject for envswith the deﬁned co-receptor phenotype. In every case, th
range. Star indicates statistically signiﬁcant difference (p b 0.05). The dashed line shows the hig
neutralized by at least 50% at the highest tested plasma dilution. For statistical comparisons, thviruses to a similar extent, which subsequently provides pressure for
envelope evolution (Moody et al., 2015). In aggregate, this suggests
that the ×X4 as compared to co-existing CCR5-using viruses have
both statistical and biological meaningful differences in neutralization
susceptibility. Thus, X4 variants are potentially neutralization escape
variants to the antibodies present in the contemporaneous autologous
plasma.
3.3. X4 Are More Resistant to Heterologous Pooled Plasma
We next hypothesized that X4 envs are escape variants from anti-
bodies often present in individuals that harbor only CCR5-using viruses.
To examine this possibility, we compared sensitivity of X4 and R5
strains to heterologous pooled R5 plasma, which was generated by
pooling plasma from 5 women documented to harbor R5 viruses only
(Lin et al., 2012). We examined 47 envs from the 4 individuals (DM8,
DM159, DM178, and DM268) in which the median IC50 against autolo-
gous contemporaneous plasmawas lower for the X4 as compared to co-
circulating R5 strains. We did not examine variants from DM146,
DM173, and DM269 because in these individuals we did not isolate
co-existing R5 and X4 strains. In all 4 individuals, the X4 viruses demon-
strated decreased sensitivity to this pooled R5 plasma compared to the
co-existing CCR5 utilizing viruses (Fig. 2a–d). Signiﬁcant differences
(p b 0.05, Wilcoxon rank sum test) were observed in 2 cases (DM178
and DM268) but not in the other 2 individuals (DM8 and DM159)
with a limited number of envs with different co-receptor usage. In ag-
gregate, X4 (median IC50: 161.7, range: 122.8–179.6) as compared to
R5 (median IC50: 425.3, range: 174.5–684.8) viruses showed a statistical
trend of around 3 fold greater neutralization resistance to the pooled R5
plasma (p=0.1, pairedWilcoxon rank sum test) (Fig. 2e). This suggests
that X4 as compared to co-existing R5 viruses are less neutralization
susceptible to antibodies commonly circulating in individuals that har-
bor only R5 variants.
3.4. X4 Variants Remain Sensitive to Antibodies Targeting env Non-co-re-
ceptor Binding Sites
It is possible that mutations in the X4 viruses compared to the R5
variants leads to a “global” antigenic change, similar to some previously
described strains (del Prete et al., 2009; Roederer et al., 2013). If the X4
as compared to the R5 variants have anoverall antigenic difference, theynt to autologous contemporaneous plasma. (a–g) Figures show neutralization IC50s for R5
lasma. Symbols represent one of the 88 independent envs from the7 subjects labeled above
tion. Figure h shows the aggregate comparisons in all subjects, and each symbol shows the
e long line represents themedian of the dot plots, and thewhiskers show the interquartile
hest tested plasma dilution (1:50). Symbols below the dotted lines are envs that were not
ese envs were assigned a midpoint value between 0 and 50.
Fig. 2. TheX4 as compared to co-circulating R5 aremore neutralization resistant to heterologous pooled R5 plasma. (a–d)Graphs showneutralization IC50s (reciprocal plasma dilution) for
R5 (circles) and X4 (boxes) viruses against heterologous pooled R5 plasma for 4 subjects. Each symbol represents one of the 47 independent envs from the 4 individuals shown above the
graph. Figure E shows the aggregate comparisons in the 4 subjects, and each symbol shows the median IC50s for the R5 or X4 envs within an individual. In every case, the long line
represents the median of the dot plots with the whiskers showing the interquartile range. Star indicates statistically signiﬁcant difference (p b 0.05). The dashed line shows the highest
tested plasma dilution (1:50).
241N. Lin et al. / EBioMedicine 8 (2016) 237–247may have different neutralization susceptibility to antibodies targeting
env regions not implicated in co-receptor binding. To explore this pos-
sibility, we assessed sensitivity to two broadly neutralizing antibodies
(bnAbs), VRC01, which targets the CD4 binding site (CD4bs) (Wu et
al., 2010, Zhou et al., 2010), and 10E8, which binds themembrane prox-
imal external region (MPER) (Huang et al., 2012). In individual subjects,
the X4 as compared to R5 viruses demonstrated similar sensitivity to
neutralization (p N 0.05, Wilcoxon rank sum test) to VRC01 (Fig. 3a–
d) and 10E8 (Fig. 3e–h). Although in some individuals the highest tested
bnAb concentration failed to yield 50% inhibition, this lack of neutraliza-
tion was observed in both the X4 and co-existing R5 variants. In these
cases, virus-antibody combination was assigned a value equivalent to
the highest tested concentration for statistical comparisons. In aggre-
gate, the median VRC01 and 10E8 IC50 of an individual's X4 and co-
existing R5 variants were not signiﬁcantly different (p N 0.05, paired
Wilcoxon rank sum test). Thus, the co-existing X4 and R5 variants dem-
onstrated equivalent sensitivity to antibodies that target env regionsnot
involved in co-receptor binding, which suggests that changes that con-
fer co-receptor switching do not lead to overall structural change in CD4
binding site or domains close to the membrane. Comparing sensitivity
to other bnAbs that target unique sites, such as the V1–V2 loop or the
interface between the trans-membrane domain and surface unit, will
need to be examined to assess structural changes in other env regions.
3.5. Infected Hosts Develop Antibodies Against X4 Variants
A study using a simian-human immunodeﬁciency virus with a sub-
type B env (SHIV-1B) has suggested that CXCR4-using variants are ex-
quisitely neutralization sensitive, and these viruses potentially arise inFig. 3. The X4 variants do not have a “global” antigenic change. Neutralization IC50s for R5 (circl
shows the bnAb concentration in μg/ml. Dotted line shows the highest tested antibody concen
neutralization at the highest tested antibody concentration were assigned an IC50 value equiv
the median of the dot plots with the whiskers showing the interquartile range.setting where there are limited nAb responses in the infected host (Ho
et al., 2007). If CXCR4 viruses emerge after immunological collapse
then infected hosts will potentially not be able to develop antibody re-
sponses against X4 variants over time.We assessed sensitivity to an au-
tologous plasma sample collected around 6months after the time point
atwhich theDM8X4 and R5 variantswere isolated to assess this notion.
The DM8 X4 compared to the co-circulating R5 variants demonstrated
similar sensitivity to plasma collected 6 month after env isolation (Fig.
S3a). Importantly, all R5 and the one X4 env were more susceptible to
the later compared to the contemporaneous plasma sample (p =
0.008, paired Wilcoxon rank sum test) (Fig. S3b). Autologous plasma
samples from later time-points were not available from other individ-
uals to further examine if infected hosts could generate nAbs against
previously circulating envs after the emergence of DM virus popula-
tions. These observations suggest that subject DM8 with a DM virus
population continues to develop humoral responses over time against
previously co-circulating R5 and X4 variants.
3.6. Neutralization Susceptibility Differences Are Inﬂuenced by env V3 Loop
Changes
Our results suggest that X4 variants are relatively insensitive to spe-
ciﬁc antibodies present in autologous plasma andheterologous antibod-
ies in individuals with only R5 circulating variants. We hypothesized
that these antibodies potentially target the env V3 loop because the
V3 loop is the primary determinant for co-receptor usage (Cann et al.,
1992). We compared sensitivity of co-existing X4 and R5 variants to
the bnAb, PGT128, because V3 loop stem sequence partially inﬂuences
susceptibility to this bnAb (Walker et al., 2011; Pejchal et al., 2011). Ines), dual-tropic (triangles), and X4 (boxes) viruses to VRC01 (a–d) and 10E8 (e–h). Y-axis
tration. For statistical comparisons, virus antibody combination that failed to yield N50%
alent to the highest tested antibody concentration. In every case, the long line represents
242 N. Lin et al. / EBioMedicine 8 (2016) 237–247DM268, X4 viruses (median IC50: 0.14 μg/ml, range: 0.04–0.22) were
N100 fold less neutralization susceptible to PGT128 compared to co-cir-
culating R5 (median IC50: 0.001 μg/ml, range: 0.001–0.02) variants
(p = 0.003, Wilcoxon rank sum test) (Fig. 4a). In contrast, neutraliza-
tion sensitivity to PGT128 for the one DM8 X4 variant (IC50: 0.41 μg/
ml) was within the range for the co-circulating R5 variants (median
IC50: 1.8 μg/ml, range: 0.37–3.67) (Fig. 4b). None of the DM159 and
DM178 X4 and R5 variants were inhibited N50% at the highest tested
PGT128 concentration (5 μg/ml), and thus an IC50s could not be calculat-
ed for comparisons.
To further examine the role of V3 loop in the observed neutralization
differences among co-circulating R5 and X4 variants, we generated V3
loop chimeric envs. In 3 subjects (DM8, DM159, and DM268) with doc-
umented differences in neutralization sensitivity among co-existing X4
and R5 variants, we exchanged V3 loops between a R5 and X4 variant.
The chimeric DM178 envs with V3 loop exchanges did not yield infec-
tious virus. Swapping the V3 loops resulted in co-receptor changes in
every case other than in DM8 (Fig. 4c–e) (Lin et al., 2012). The chimeric
envs with X4 V3s were less sensitive to pooled R5 heterologous plasma
compared to the envs containing the R5 V3 loops in every case. The dif-
ferences, however,were relatively small especially compared to the sus-
ceptibility differences among the original envs. Furthermore, in both
DM268 and DM8, introduction of an X4 V3 loop within the R5 back-
ground yielded a virus with greater resistance to PGT128 compared to
the original env or the recombinant with a R5 V3 loop (Fig. 4f–g). In ag-
gregate, these results suggest that the V3 loop potentially inﬂuences the
observed neutralization differences among co-circulating R5 and X4
variants.
ELISAs were used to further examine V3 directed antibody binding
variation to co-existing DM268 X4 and R5 variants. We only assessed
DM268 envs because of the observed sensitivity difference to bnAb,
PGT128. We generated gp120 proteins based on the predicted amino
acids in a DM268 R5 variant (clone M). One gp120 contained an R5
V3, DM268-M-R5V3, and the other harbored an X4 V3 from clone Y,
DM268-M-X4V3. Both contained a D368R mutation to avoid CD4 inter-
ference (Olshevsky et al., 1990). As expected, the CD4 binding site bnAb,
VRC01, showed no binding to either gp120 because of the D368Rmuta-
tion (Fig. 5a). On the other hand, both gp120s showed relatively equiv-
alentweak binding to CD4-Ig (Fig. 5b),which is similar towhat has been
shown with other gp120s containing the D368R mutation (Jia et al.,
2016). The DM268-M-R5V3 gp120 as compared to DM268-M-X4V3,Fig. 4.Neutralization susceptibility differences amongX4 andR5 viruses are inﬂuencedby envV
different co-receptor usage in DM268 (a) and DM8 (b). Figures c–g show IC50 against pooled R
original X4 (black), env with a R5 V3 loop in a X4 background (gray) or X4 V3 loop in a R5 ba
denotes the env clone followed by the observed co-receptor usage in parenthesis. Star deno
chimeric env MYMwas not infectious (Lin et al., 2012).however, showed markedly greater binding to PGT128 (Fig. 5c), V3
loop crown antibody, 447-52D (Fig. 5d), and contemporaneous autolo-
gous serum (Fig. 5e) (Gorny et al., 1992). Although, 447-52D demon-
strated ELISA binding, this mAb was unable to neutralize any
DM268M variant at the highest tested concentration (5 μg/ml) (data
not shown). These ELISA results suggest that theDM268 plasmaharbors
anti V3 loop antibodies that preferentially bind R5 but not X4 envs.
Neutralization competition experimentswere carried out to assess if
thepresence anti V3 loop antibodies in the autologous plasma is respon-
sible for the differential neutralization of DM268 R5 and X4 variants. If
anti V3 loop antibodies that preferentially bind R5 but not X4 envs
were primarily responsible for neutralization susceptibility differences
among DM268 X4 and R5 variants, it would be expected that gp120s
with R5 but not X4 V3 would prevent autologous contemporaneous
plasma from neutralizing the virus. In the presence of DM268-M-R5V3
gp120 (reciprocal plasma dilution IC50: 132.1) neutralization of the
DM268M virus required greater amount of plasma compared to in the
presence of DM268-M-X4V3 gp120 (reciprocal plasma dilution IC50:
168.3) or the absence of gp120 (reciprocal plasma dilution IC50:
200.0) (Fig. 6). These estimated IC50 differences, however, were not sta-
tistically signiﬁcantly different. This suggests that even though the plas-
ma contains anti V3 loop antibodies that preferentially bind R5 but not
X4 gp120s, these antibodies had a small impact in neutralizing a DM268
R5 strain.
3.7. Emergence of CXCR4-using Virus With Serial Passage in Plasma
To understand if CXCR4-using variants emerge from R5 viruses as a
consequence of nAb pressure, we independently passaged a neutraliza-
tion sensitive R5 variant from 3 different subjects (DM8, DM178, and
DM268) in activated CD4+ T cells in the absence or presence of heat
inactivated contemporaneous autologous plasma (Fig. 7a–c). While all
the previous experiments used pseudovirions with full-length envs,
replication competent recombinant viruses were used in these pas-
sages. These replication competent recombinant viruses incorporated
an individual's neutralization sensitive R5 env ecto-domain rather
than the full-length env. Incorporation of full-length envs within a het-
erologous HIV-1 backbone did not yield infectious virus. In all 3 cases,
virus passaged in the presence as compared to the absence of autolo-
gous plasma yielded virus supernatants that were neutralization resis-
tant (Fig. 7d–f). Passage of DM268M R5 variant in the presence but3 loop. Figures a–b showmean IC50s (μg/ml) to PGT128 among co-circulating variantswith
5 plasma (reciprocal dilution) (c–e) and PGT128 (μg/ml) (f–g) for the original R5 (white),
ckground (checkers). In each graph, the subject is denoted above. Label below the x-axis
tes signiﬁcant p-value for the comparison (p b 0.05, Wilcoxon rank sum test). DM268
Fig. 5. Co-circulating R5 and X4 viruses have different reactivity to anti-env V3 loop antibodies and autologous plasma. Figure a thru e show ELISA binding proﬁles of the DM268_D368R
gp120with either a R5 V3 loop (circle) or X4 V3 loop (square) to VRC01 (a), CD4-Ig (b), PGT128 (c), 447-52D (d), and autologous contemporary plasma (e). The y-axis shows the OD and
the x-axis shows the antibody concentration or plasma dilution.
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tologous plasma led to the emergence of a CXCR4-using virus (Fig. 8a–
b). The day 75DM268 virus supernatant passaged in the presence as op-
posed to the absence of autologous plasma replicated in U87–CXCR4
cells that lacked the CCR5 receptor (Fig. 8a). Replication decreased in
the presence of CXCR4 inhibitor, AMD3100, suggesting that cell entry
was mediated by engaging the CXCR4 co-receptor. CXCR4 usage was
highly inefﬁcient because day 75 plasma passaged DM268 virus super-
natant yielded nearly 10 fold less HIV-1 antigen (p24gag) in the U87–
CXCR4 as compared to U87–CCR5 cells (Fig. 8b). Similar results were
observed with day 68 DM268 virus supernatant passaged in the pres-
ence of autologous plasma (data not shown). In contrast, all other
virus supernatants passaged either in the absence or presence of plasma
infected U87–CCR5 cells but not U87–CXCR4 cells.
We hypothesized that the day 75 DM268 virus stock passaged in the
presence of plasma (DM268 + plasma-d75) contained a possible mix-
ture of R5, R5X4, and X4 viruses. To efﬁciently isolate the CCR5- versus
CXCR4-using viruses in DM268+ plasma-d75, we examined viruses in
the U87–CXCR4 and U87–CCR5 cell culture supernatants. We reasoned
that the U87–CXCR4 and the U87–CCR5 cell culture supernatants
should only contain CXCR4- and CCR5-utilizing viruses respectively. In-
terestingly, the culture supernatants from the U87–CCR5 and U87–
CXCR4 cells exposed to DM268 + plasma-d75 showed identical env
bulk sequences. This suggests that passage in thepresence of autologous
plasma led to the emergence of a neutralization resistant R5X4 variant
with relatively inefﬁcient CXCR4 usage. Surprisingly, this R5X4 variant
had an amino acid change at position 88 (HXB2 numbering), which in-
troduced a predicted asparagine (N) linked glycosylation site (PNGS)
(Fig. S4). In contrast, passage in the absence of plasma generated virus
stocks that contained a mixture of amino acids at 2 positions but was
otherwise invariant from the starting input virus. Interestingly, all
other R5 and X4 DM268 variants (n = 17) previously isolated fromFig. 6. gp120swith different envV3 loops fails to prevent neutralization. Percent inhibition
observed in the absence or presence of DM268_D368R gp120 with R5 V3 or X4 V3. The y-
axis shows the percent inhibition and the x-axis shows the reciprocal plasma dilution.this individual harbored the PNGS at position 88. Site directedmutagen-
esis could not be used to assess if this modiﬁcationwould change co-re-
ceptor usage in other strains because all other isolated R5 envs
contained the position 88 PNGS. The effect of the position 88 change
on co-receptor usage, however, is context dependent because none of
the other previously isolated DM268 env variants with a position 88
PNGS were able to use both the CCR5 and CXCR4 co-receptor for cell
entry. These observations imply that passage in the presence of autolo-
gous plasma led to the emergence of a PNGS at position 88, which sub-
sequently conferred CXCR4 usage.
4. Discussion
This study demonstrates that X4 variants aremore neutralization re-
sistant compared to R5 and R5X4 viruses and provides a potential bio-
logical mechanism for HIV-1 co-receptor switching. In multiple
subjects, we show that co-existing X4 as compared to R5 variants are
more resistant to antibodies present in autologous contemporaneous
and heterologous pooled plasma from individuals with only R5 strains.
This decreased neutralization sensitivity did not result from changes
that led to a global antigenic change. Thus, this argues that X4 viruses
are more resistant to certain antibodies, likely against the env V3 loop,
generated by the infected individual. Furthermore, we show that pas-
sage of neutralization sensitive CCR5-using variants in the presence of
increasing concentrations of autologous contemporaneous plasma was
sufﬁcient to force the evolution of a CXCR4-using virus from anR5 strain
in 1 of 3 subjects. In aggregate, our studies suggest that humoral im-
mune pressure can drive the emergence of CXCR4-utilizing viruses in
some individuals.
Studies have suggested that dual-tropic strains evolve from R5 vari-
ants, and X4 viruses arise from the R5X4 strains (Pastore et al., 2004). It
is unlikely that the emergence of a dual-tropic virus during the passage
experiments occurred by chance because CXCR4-using variants were
not detected in the absence of plasma and changes required for co-re-
ceptor switching are generally associated with diminished replication
ﬁtness (Pastore et al., 2004). TheDM268passage resultswere surprising
because we observed no signiﬁcant neutralization susceptibility differ-
ence to contemporaneous autologous plasma among co-existing R5
and dual-tropic strains (Fig. 1). Although previous studies have demon-
strated that diverse glycosylation changes can render viruses neutrali-
zation resistant (Sagar et al., 2006, Wei et al., 2003), it remains unclear
how the addition of PNGS at position 88 leads to low level CXCR4
usage. It has been shown that co-circulating R5 and R5X4 variants
often have the same predicted V3 loop sequence (Huang et al., 2007;
Lin et al., 2012), and thus it possible thatmodiﬁcations in other env seg-
ments lead to a structural change that can inﬂuence co-receptor usage.
Interestingly, DM viruses did not emerge in the other 2 cases (DM8 and
DM178) even though their X4 as compared to R5 envs were more neu-
tralization resistant to autologous contemporaneous plasma. Our obser-
vations suggest that the passaged DM8 and DM178 env variants
Fig. 7. Passage in the presence of autologous contemporaneous plasma leads to neutralization resistant virus. Figure a thru c show passage of DM8 clone S (a), DM178 clone A (b), and
DM268 clone M (c) in the absence (circle) or presence (square) of autologous contemporaneous plasma. In each graph, the x-axis shows the days post-infection. The left y-axis shows
the estimated p24 concentration in the culture and the right y-axis shows contemporaneous autologous plasma dilution in the culture (triangles). Figures d thru f show neutralization
susceptibility of passaged virus stock to contemporaneous autologous plasma. The y-axis shows the percent inhibition and the x-axis shows the reciprocal of the autologous plasma
dilution. Any virus/plasma combination that did not show a positive inhibition value was assigned a % inhibition of 10% to improve visualization on the graph. Virus stocks passaged in
the presence (square) or absence of (circle) of autologous plasma were from day 34 (DM8) (d), day 92 (DM178) (e), and day 75 (DM268) (f) post-infection.
244 N. Lin et al. / EBioMedicine 8 (2016) 237–247accommodated changes required for neutralization resistance to autol-
ogous plasma without co-receptor switching. Other R5 variants from
these individuals, not examined in the passaging experiments, may ac-
quire the ability to use the CXCR4 receptor as they become resistant to
autologous antibodies.
The earliest studies implied that lab-adapted SI, presumably CXCR4-
using, strains were more neutralization sensitive compared to NSI–
CCR5-utilizing variants (Mascola et al., 1996; Monteﬁori et al., 1998;Fig. 8. A CXCR4-using virus emerged with passage in the presence as opposed to the absence o
cells for day 34 (DM8), day 92 (DM178), and day 75 (DM268) virus stocks. The table below ind
plasma. The table also shows replication observed in the presence (white bars) or absence (bl
replication of control viruses NL43 (X4) and YU-2(R5). Each bar shows standard error from
Cultures in which the p24 antigen level was below the limit of detection were assigned a valuD'Souza et al., 1997; Sawyer et al., 1994). Subsequent studies showed
that compared to CCR5-utilizing strains primary as opposed to lab-
adapted CXCR4-using envs displayed a relatively similar range of neu-
tralization susceptibilities to some mAbs and unrelated heterologous
plasma (Trkola et al., 1998; Monteﬁori et al., 1998; Cecilia et al., 1998;
Lacasse et al., 1998). This led to the notion that nAbs are unlikely to be
the major selection pressure that drives co-receptor switching. Our re-
sults also show that X4 and co-existing R5 variants have equivalentf autologous plasma in DM268. Replication in U87-CD4-CXCR4 (a) and U87-CD4-CCR5 (b)
icates whether the virus stock was from passage in the presence or absence of autologous
ack bars) of speciﬁc CXCR4 (AMD3100) and CCR5 (TAK779) inhibitors. Graphs also show
2 independent measurements. Dotted line shows the limit of detection (25 pg/ml).
e midpoint between 0 and 25 to improve visualization on the graph.
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ceptor binding.More recent investigationswith SHIV-1B andHIV-1B in-
fected subjects argue that relatively neutralization sensitive CXCR4-
utilizing variants emerge later in disease after HIV-1 induced immuno-
logical damage has led to a compromised humoral immune response
(Bunnik et al., 2007; Ho et al., 2007). We, however, observed no case
in which X4 or R5X4 as compared to co-circulating R5 envs were signif-
icantlymore neutralization susceptible to autologous contemporaneous
plasma, even though we sampled more envs from each subject and ex-
amined a greater number of individuals. Furthermore, the previous
human study examined PBMC passaged variants (Bunnik et al., 2007),
which may have led to the different results because passaging virus in
PBMCs signiﬁcantly impacts its neutralization properties in a unique
manner for each virus antibody combination (Etemad et al., 2015;
Provine et al., 2012).
Our results also differ from the previous human study (Bunnik et al.,
2007) potentially because we examined HIV-1C versus HIV-1B infected
individuals. Our preliminary results, however, suggest this is not the
case (Fig. S2). While HIV-1C constitutes the majority of worldwide in-
fections, emergence of CXCR4 usage occurs at a lower frequency com-
pared to HIV-1B (Lin et al., 2011; Ataher et al., 2012). Reasons for the
difference in incidence remain uncertain. Although it has been reported
that CCR5 and CXCR4-using viruses preferentially infect memory and
naïve T cells respectively (Davenport et al., 2002; Blaak et al., 2000),
there is no evidence that this preference differs among HIV-1B versus
HIV-1C variants (Cashin et al., 2014; Ribeiro et al., 2006). While, it is
known that the CCR5Δ32 allele frequency is higher among Europeans
than Africans (Galvani and Novembre, 2005), the density of the CCR5
receptor on CD4+ T cells is not signiﬁcantly different among people
with European ancestry who constitute the majority of HIV-1B infec-
tions versus those with African heritage who are predominantly infect-
ed with HIV-1C (Picton et al., 2012). Thus, the higher incidence of DM
virus population in HIV-1B as compared to HIV-1C infected individuals
is unlikely because of lower availability of appropriate CCR5 expressing
target cells. It has been suggested that HIV-1B and HIV-1C envs have
structural differences, especially in the V3 loop (Patel et al., 2008). Po-
tentially in response to these env structural differences, HIV-1C infected
individuals develop antibodies targeting the C3-V4 region while those
with HIV-1B generate responses against the V1-V2 domain and the
base of the V3 loop (Rong et al., 2009, Moore et al., 2008; Tang et al.,
2011). Interestingly, the main determinants for co-receptor switching
are located in the V1 to V3 domains (O'Brien et al., 1990; Chesebro et
al., 1991; Shioda et al., 1992; Groenink et al., 1993; Fouchier et al.,
1995). Greater prevalence of anti-V1-V2 or V3 loop antibodies may cor-
relate with the greater frequency of DM virus populations in HIV-1B as
compared to HIV-1C infected individuals.
While most HIV-1 infected individuals develop nAbs against their
circulating variants and viruses escape this humoral pressure, there
are potentially two important factors that explain why CXCR4-
using variants do not evolve in everyone. First, CXCR4-utilizing vi-
ruses will not emerge if the circulating env variants cannot accom-
modate changes required for CXCR4 usage regardless of the
selection pressure. Both laboratory and human studies have docu-
mented that some HIV-1 env variants do not evolve to use the
CXCR4 receptor even in setting where they are exposed to CCR5 in-
hibitors (Westby et al., 2007; Marozsan et al., 2005; Tsibris et al.,
2008). Second, similar to the observation that some but not all HIV-
1 infected individuals develop cross-neutralizing antibodies (Doria-
Rose et al., 2009), co-receptor switching due to humoral selection
may only occur in people that develop certain types of antibodies
over the course of infection. Thus, in people that do not generate an-
tibodies with the appropriate speciﬁcity neutralization escape may
occur without changes in co-receptor usage. Unfortunately, we did
not have access to live PBMCs to generate mAbs from these individ-
uals, which would have allowed us to map the epitope for the anti-
bodies that neutralize R5 but not co-existing X4 variants.Interestingly, treatment of HIV-1 infected humanized mice with
anti-V3 loop bnAb, PGT128, but not anti-CD4bs bnAb, 45-46GW, has
been predicted to select for a signiﬁcantly higher proportion of
CXCR4-using variants (Pfeifer et al., 2014). Furthermore, CXCR4 as com-
pared to CCR5-using variants are overrepresented among variants resis-
tant to env V1–V2 directed bnAbs, PG9 and PG16. Thus similar to our
suggestions, this investigation implies that antibodies directed against
the env variable loops potentially select for neutralization resistant
CXCR4-utilizing variants (Pfeifer et al., 2014). One study has argued
that this may also be the case during longitudinal HIV-2 infection
(Marcelino et al., 2012). Even though our conclusions are based on ob-
servations from a small number of individuals, and in some cases only
a limited number of envs with different co-receptor phenotype, our
studies strongly support the idea that X4 variants are neutralization es-
cape variants.
In contrast to the previously proposed mechanisms that lead to co-
receptor switching, such as random mutations, waning immunity,
and/or decreasing number of CCR5+ T cells, our observations suggest
that antibody pressure selects for CXCR4-utilizing variants (Regoes
and Bonhoeffer, 2005). It is likely that in some but not necessarily all in-
dividuals that eventually develop CXCR4-using viruses antibodies force
env structural changes that directly inﬂuence co-receptor switching.
Continual presence of these humoral responses eventually leads to the
emergence of X4 variants resistant to these and other host generated
anti V3 antibodies. This new biological mechanism for co-receptor
switching has a number of important implications. It is generally agreed
that presence of CXCR4-using variants leads to faster CD4 decline and
earlier onset of AIDS (Koot et al., 1993; Richman and Bozzette, 1994;
Connor et al., 1997), although the causal link is unclear. Our studies
would argue that an infected individual's humoral immune response
leads to the emergence of CXCR4-utilizing variants, which results in
an adverse outcome. Thus, our observations imply that CXCR4-using
variants cause and are not a result of decreasing immunity. Importantly,
this suggests that in some individuals, the humoral immune response
against their autologous virus worsens infection outcome. Although an-
tibodies have been suggested to adversely affect disease progression in
other viral infections, notably dengue and inﬂuenza, no previous study
has implied this for HIV-1 (Halstead and O'Rourke, 1977; Khurana et
al., 2013). In addition, in contrast to dengue or inﬂuenzawhere antibod-
ies enhance entry of the infecting virus into host cells, our studies sug-
gest a mechanism where antibodies force phenotypic changes in
replicating variants to expand the cellular tropism. Finally, our results
have implications for proposed strategies of using bnAbs as prophylaxis,
treatment, or cure (Caskey et al., 2015; Lynch et al., 2015). Our results
and previous studies suggest that speciﬁc antibodiesmay be less potent
against CXCR4-utilizing variants, which may select for their emergence
in settings where antibodies are unable to fully inhibit virus replication
(Pfeifer et al., 2014). Thus, the bnAbs selected for immunotherapy will
need to be evaluated carefully to ensure that they do not promote the
emergence of CXCR4-using strains, which can accelerate disease pro-
gression among infected individuals.Funding Sources
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